Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores [0.03%]
纳米白蛋白结合型紫杉醇联合吉西他滨一线治疗转移或复发性胰腺癌患者的预后因素：基于炎症的评分的影响
Inhwan Hwang,Jihoon Kang,Hei Nga Natalie Ip et al.
Inhwan Hwang et al.
Background Nab-paclitaxel plus gemcitabine (AG) is standard first-line chemotherapy for patients with metastatic pancreatic cancer (mPC). However, prognostic factors for patients with mPC treated with AG, are largely unknown. We retrospecti...
Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases [0.03%]
晚期或复发性胆道癌二线化疗一项单中心回顾性分析(294例)
Naminatsu Takahara,Yousuke Nakai,Hiroyuki Isayama et al.
Naminatsu Takahara et al.
Purpose The survival benefit of first-line chemotherapy (CT1) for biliary tract cancer (BTC) is now established but the role of second-line chemotherapy (CT2) has not been fully elucidated yet. Methods Consecutive advanced BTC patients rece...
Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens [0.03%]
加拿大癌症试验组（CCTG）IND215：一项关于塞利帕利联合标准化学疗法治疗未经治疗的晚期或转移性NSCLC患者的Ib期研究
J R Goffin,G Nicholas,M Mates et al.
J R Goffin et al.
Introduction Selumetinib (AZD6244, ARRY-142886) is a potent inhibitor of MEK1/2, thereby inhibiting phosphorylation of ERK2. We investigated the toxicity and the recommended phase II dose of the combination of selumetinib with two platinum ...
Clinical Trial
Investigational new drugs. 2019 Jun;37(3):498-506. DOI:10.1007/s10637-018-0680-z 2019
Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials [0.03%]
I期临床试验中结直肠癌患者的生存结果和预后模型
Audrey E Kam,Gopichand Pendurti,Umang H Shah et al.
Audrey E Kam et al.
Background Patients with metastatic colorectal cancer (mCRC) who progress on standard therapies may be eligible for phase I trials. To better delineate the risk-benefit ratio, we assessed toxicities, clinical outcomes and prognostic factors...
Clinical Trial
Investigational new drugs. 2019 Jun;37(3):490-497. DOI:10.1007/s10637-018-0675-9 2019
A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β [0.03%]
伊马替尼和来曲唑治疗激素受体阳性且表达c-kit或PDGFR-β的转移性乳腺癌患者的II期临床研究
Clinton Yam,Rashmi K Murthy,Gaiane M Rauch et al.
Clinton Yam et al.
Background Imatinib mesylate is a potent inhibitor of the Abl, KIT and platelet derived growth factor (PDGF) receptor tyrosine kinases. Preclinical data suggest that combining imatinib mesylate with anti-estrogen therapy may be synergistic ...
Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first-line treatment of metastatic colorectal cancer [0.03%]
依维莫司联合mFOLFOX-6和贝伐珠单抗一线治疗转移性结直肠癌的Ⅰ/Ⅱ期临床研究
G Weldon Gilcrease,David D Stenehjem,Mark L Wade et al.
G Weldon Gilcrease et al.
Background This phase I/II trial evaluated toxicity and antitumor activity of everolimus plus mFOLFOX6 + bevacizumab for first-line treatment of metastatic colorectal cancer (mCRC). Methods A phase I, modified 3 + 3 Fibonacci schema determi...
Clinical Trial
Investigational new drugs. 2019 Jun;37(3):482-489. DOI:10.1007/s10637-018-0645-2 2019
Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer [0.03%]
恩杂鲁胺联合吉西他滨和白蛋白结合型紫杉醇治疗晚期胰腺癌的Ⅰ期临床试验
Amit Mahipal,Sri Harsha Tella,Anuhya Kommalapati et al.
Amit Mahipal et al.
Background Androgens were shown to play a key role in the growth and progression of pancreatic cancer. We evaluated the safety and tolerability of the combination of enzalutamide, a novel androgen receptor (AR) antagonist with gemcitabine a...
Clinical Trial
Investigational new drugs. 2019 Jun;37(3):473-481. DOI:10.1007/s10637-018-0676-8 2019
Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review [0.03%]
免疫检查点抑制剂在终末期肾病透析患者中的安全性和有效性：病例系列及文献回顾
Hyeon Cheun,Miso Kim,Hajeong Lee et al.
Hyeon Cheun et al.
Despite the lack of safety and efficacy data regarding immune checkpoint inhibitors (ICIs) for renal dysfunction, they have been approved to treat even in the patients with end-stage renal disease (ESRD). We report our experience with ICI a...
Clinical outcomes of patients with G1/G2 neuroendocrine tumors arising from foregut or hindgut treated with somatostatin analogs: a retrospective study [0.03%]
生长抑素类似物治疗胃肠道G1/G2神经内分泌肿瘤患者的临床结局：一项回顾性研究
Hanae Ida,Yoshitaka Honma,Hidekazu Hirano et al.
Hanae Ida et al.
Neuroendocrine tumors (NET) are rare tumors for which somatostatin analogs (SSA) are used not only for symptom control due to a functioning tumor, but also for the disease control of unresectable NET. The efficacy of SSA for midgut NET has ...
E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases [0.03%]
E6201（一种静脉注射给药的MEK1抑制剂）在BRAF V600E突变型黑色素瘤脑转移患者中表现出良好的疗效
Hani M Babiker,Sara A Byron,William P D Hendricks et al.
Hani M Babiker et al.
Malignant melanoma (MM) exhibits a high propensity for central nervous system dissemination with ~50% of metastatic MM patients developing brain metastases (BM). Targeted therapies and immune checkpoint inhibitors have improved overall surv...
Clinical Trial
Investigational new drugs. 2019 Aug;37(4):636-645. DOI:10.1007/s10637-018-0668-8 2019